Veradermics, Inc Payments to Acquire Debt Securities, Available-for-sale
Veradermics, Inc (MANE) reported Payments to Acquire Debt Securities, Available-for-sale of $428.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- Veradermics, Inc payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $305.58M, a 3568.39% increase year-over-year.
- Veradermics, Inc payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $122.99M, a 681.82% increase year-over-year.
- Veradermics, Inc payments to acquire debt securities, available-for-sale for the quarter ending 2025-06-30 was $8.33M.
- Veradermics, Inc payments to acquire debt securities, available-for-sale for the quarter ending 2025-03-31 was $15.73M.
- Veradermics, Inc payments to acquire debt securities, available-for-sale for fiscal 2025 was $143.85M.
- Veradermics, Inc payments to acquire debt securities, available-for-sale for fiscal 2024 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|
| 2026-06-30 | $305.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $428.56M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $122.99M 10-Q · filed 2026-05-12 | ||
| 2025-12-31 | $143.85M 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $8.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $24.06M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $15.73M 10-Q · filed 2026-05-12 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |